Novo Nordisk India is slashing prices for its semaglutide injections starting April 1, 2026. Patients with type 2 diabetes or weight management needs will see the starting dose of Ozempic drop by 36%, while the entry-level dose of Wegovy will be reduced by 48%.

The new prices in India for Ozempic and Wegovy across dosages effective April 1, 2026, are as follows: 

Ozempic (0.25 mg) and Wegovy (0.25 mg) will now be available in India at an effective daily price of Rs. 202 or a weekly price of Rs. 1,415 inclusive of taxes. This is done to make these innovative therapies, that are supported by robust clinical evidence and high scientific standards, more accessible to a larger section of people living with diabetes and obesity in India. 

Ozempic is the only GLP-1 RA with the broadest range of benefits for people with type 2 diabetes (PwT2D), proven to provide significant glycaemic control, compelling weight loss, along with risk reduction of cardiovascular and kidney events in PwT2D.

Wegovy delivers quality and sustainable weight loss with proven cardiovascular benefits in people living with overweight/obesity. Both are indicated adjunct to diet and exercise and are prescription only medications that should be used in line with their approved indication under the supervision of a healthcare professional. 

Novo Nordisk’s semaglutide, the active pharmaceutical ingredient in Wegovy and Ozempic, is backed by 50+ clinical trials, 49 million patient years of exposure, and extensive real-world evidence. Both therapies are manufactured using rDNA technology, are available in a pen device with established safety standards, and follow a robust nation-wide cold chain management process. For patients, this translates into a treatment option with a well‑established safety and efficacy profile. Injectable semaglutide is approved by regulatory authorities across 75 countries including the Drugs Controller General of India (DCGI), European Medicines Agency (EMA), United States Food & Drug Administration (US FDA) and Pharmaceuticals and Medical Devices Agency (PMDA), Japan. 

Commenting on this move, Vikrant Shrotriya, Managing Director, Novo Nordisk India said, “We’re driven by science, but our focus is always on patients. By revising the price of our innovative treatments, we’re trying to make best-in-class cardiometabolic care more affordable for as many people with type 2 diabetes, overweight and obesity in India as possible. We’ve heard from patients and doctors, and we’re acting on that feedback. The burden of diabetes, obesity and related complications is immense for India, and we aim to bend this curve with effective, safe, and time-tested solutions.”